Doxorubicin‐loaded nanoparticle coated with endothelial cells‐derived exosomes for immunogenic chemotherapy of glioblastoma

• Main Authors: Chao Zhang (Author), Jian Song (Author), Lei Lou (Author), Xuejiao Qi (Author), Lei Zhao (Author), Bo Fan (Author), Guozhu Sun (Author), Zhongqiang Lv (Author), Zhenzeng Fan (Author), Baohua Jiao (Author), Jiankai Yang (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2380-6761; 10.1002/btm2.10203
• Keywords: blood brain barrier; doxorubicin; exosome‐coated doxorubicin‐loaded nanoparticle; glioblastoma; immunogenic cell death; Chemical engineering; TP155-156; Biotechnology; TP248.13-248.65; Therapeutics. Pharmacology; RM1-950
• Source: Bioengineering & Translational Medicine, Vol 6, Iss 3, Pp n/a-n/a (2021)

Abstract Treatments of glioblastoma (GBM) have not been very effective, largely due to the inefficiency of drugs in penetrating the blood brain barrier (BBB). In this study, we investigated the potential of exosome‐coated doxorubicin (DOX)‐loaded nanoparticles (ENPDOX) in BBB penetration, inducing immunogenic cell death (ICD) and promoting survival of GBM‐bearing mice. DOX‐loaded nanoparticles (NPDOX) were coated with exosomes prepared from mouse brain endothelial bEnd.3 cells. ENPDOX cellular uptake was examined. Penetration of ENPDOX through the BBB was tested in an in vitro transwell system and a GBM mouse model. The effects of ENPDOX in inducing apoptosis and ICD were assessed. Finally, the efficacy of ENPDOX in the treatment of GBM‐bearing mice was assessed. ENPDOX was taken up by bEnd.3 cells and could penetrate the BBB both in vitro and in vivo. In vitro, ENDDOX induced apoptosis and ICD of glioma GL261 cells. Systemic administration of ENPDOX resulted in maturation of dendritic cells, activation of cytotoxic cells, altered production of cytokines, suppressed proliferation and increased apoptosis of GBM cells in vivo and prolonged survival of GBM‐bearing mice. Our findings indicate that ENPDOX may be a potent therapeutic strategy for GBM which warrants further investigation in clinical application.